🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's series of deals with the US administration are "fundamentally unstable." This comes after revelations that a much-touted deal on medicines, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond limited headline terms published in government press releases.

Lacking Legal Footing

The arrangement concerning medicines, described as a "generational" achievement, exists as an "statement of intent" without detailed provisions. It has been highlighted that the official announcements from the UK and US governments describe the deal in markedly contrasting terms. The British version emphasizes securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the commitment for the NHS to pay significantly more for new medications.

"There is a serious risk that the UK government has promised concessions to increase medicine costs in return for only a verbal promise from President Trump," stated David Henig, a trade expert. "It is documented he has form for not keeping promises."

A Pattern of Unreliability

Anxieties have been amplified by Washington's recent decision to suspend the major technology agreement, which was previously called "a transformative pact" in the bilateral relationship. The US pointed to a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

In a separate development, concessions promised for British farmers as part of an May trade agreement have yet to be formally signed off by the US, despite a fast-approaching January deadline. "It is our belief that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have expressed concerns that the government's US-UK accords are unstable and unpredictable. One minister reportedly said the series of agreements as "resting on shaky ground," while another framed the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than the administration's tactics is the UK government's credulous faith that his administration is a reliable partner. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have attempted to minimize the possibility of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that unpredictability is part and parcel of dealing with the current US leadership. However, they contend that the UK has obtained tangible results for businesses, such as preferential tariff rates compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, problems have emerged in carrying out the broader trade deal. Promised quotas on beef exports have not materialized, and the pledge to "reduce steel tariffs to zero" has is still pending, with tariffs staying at 25%.

Moving forward, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.